Evidence map›Paper›PMID 38247507›Full record

ReviewAntioxidants (Basel, Switzerland)2024

Targeting Cysteine Oxidation in Thrombotic Disorders.

Moua Yang, Roy L Silverstein

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Best practices for cysteine analysis.Ferroptosis and oxidative stress · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Moua YangDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, 3 Blackfan Circle, CLS-924, Boston, MA 02115, USA.ORCID 0000-0001-6340-457X
Roy L SilversteinDepartment of Medicine, Medical College of Wisconsin, Hub 8745, 8701 W Watertown Plank Rd., Milwaukee, WI 53226, USA.
Beth Israel Deaconess Medical Center · USMedical College of Wisconsin · US

Funding

ERK5 and CD36 link oxidative stress to platelet dysfunction and ischemic injuryR01HL142152 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI MORRELL, CRAIG N, SILVERSTEIN, ROY L · 2019 to 2022
$2.5M
NKA/CD36 signaling in adipocytes promotes oxidative stress and drives chronic inflammation in atherosclerosisR01HL164460 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Yiliang Chen, Roy L Silverstein · 2023 to 2026
$2.1M
Pim1 kinase coordinates PPAR gamma pathway and mitochondrial function to mediate pro-atherogenic responses in macrophagesR01HL153397 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI CUI, WEIGUO, SILVERSTEIN, ROY L · 2021 to 2024
$1.7M
Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell DiseaseK99HL164888 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI YANG, MOUA · 2022 to 2023
$329k
NHLBI NIH HHS K99 HL164888NHLBI NIH HHS R01 HL142152NHLBI NIH HHS R01 HL153397NHLBI NIH HHS R01 HL164460
6 · The paper itself

Abstract

Oxidative stress increases the risk for clinically significant thrombotic events, yet the mechanisms by which oxidants become prothrombotic are unclear. In this review, we provide an overview of cysteine reactivity and oxidation. We then highlight recent findings on cysteine oxidation events in oxidative stress-related thrombosis. Special emphasis is on the signaling pathway induced by a platelet membrane protein, CD36, in dyslipidemia, and by protein disulfide isomerase (PDI), a member of the thiol oxidoreductase family of proteins. Antioxidative and chemical biology approaches to target cysteine are discussed. Lastly, the knowledge gaps in the field are highlighted as they relate to understanding how oxidative cysteine modification might be targeted to limit thrombosis.

Indexed as

CD36cysteinenucleophilesoxidative stressplateletsprotein disulfide isomerasethrombosis

Identifiers

PMID38247507
PMCPMC10812781
OpenAlexW4390725293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.